MedTrace Logo

Effect of Weight and/or Obesity on Caspofungin Drug Concentrations

NCT01062165 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-02-10

Study results available
· View outcomes & findings →

Summary

This study will find how weight affects the dosing of a drug called caspofungin. Currently, the amount of caspofungin a patient receives is the same regardless of the patient's weight.

Conditions

Interventions

DRUG

Caspofungin

Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Ronald Hall, PharmD, MSCS · Texas Tech University HSC

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062165 on ClinicalTrials.gov